“Blind spots of insurance benefits on hepatitis C therapies, Sovaldi & Harvoni, will be resolved”
The hepatitis C treatment, ‘Harvoni(ledipasvir+sofosbuvir),’ will also be applied for the health insurance benefit even if the Dak-Sun combination therapy cannot be used.
Side effects which has been indicated as blind spots of the Harvoni’s insurance benefit application were also included, such ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
